Prolific biotech investor plans SPAC just three months after taking an eye disease treatment company public through a merger with its first blank check company.VC sets up a 2nd ‘blank check’ company targeting white-hot biotech market
Prolific biotech investor plans SPAC just three months after taking an eye disease treatment company public through a merger with its first blank check company.